Related Experiment Video
Updated: Aug 7, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
New therapies in non-small cell lung cancer with EGFR exon 20 insertion mutations
Gil-Sierra Manuel David1, Briceño-Casado Maria Del Pilar2, Moreno-Ramos Cristina2
1Pharmacy Department, Hospital Universitario de Jerez de la Frontera, Jerez de la Frontera, Cádiz, Spain.
Objective:
Patients with non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 20 insertion mutations have a poor prognosis and few therapeutic alternatives. We conducted a review of scientific evidence about therapies in NSCLC with EGFR exon 20 insertion mutations.
Data Sources:
A systematic review in PubMed® database was performed up to November 19, 2022. Clinical trials (CTs) about treatments of patients diagnosed with advanced or metastatic NSCLC harbouring EGFR exon 20 insertions who had previously received platinum-based chemotherapy were selected. CTs with a sample size of less than 10 patients were discarded. Efficacy results were used to determine the most interesting drugs. Subsequently, a more exhaustive analysis of the design of the CTs and safety of the most interesting schemes was conducted. Comparisons were attempted to develop.
Data Summary:
A total of 40 records were found in the systematic search. Twelve selected CTs included the following therapies: poziotinib, osimertinib, pertuzumab-trastuzumab-docetaxel scheme, mobocertinib, amivantamab, erlotinib-onalespib regimen, luminespib, ado-trastuzumab emtansine and dacomitinib. Mobocertinib, amivantamab and poziotinib were determined as the most interesting treatments according to efficacy data. Gastrointestinal and dermatological adverse reactions were relevant in these regimens. All CTs presented a non-randomised design. No reliable comparisons could be developed.
Conclusions:
The efficacy of mobocertinib, amivantamab and poziotinib in NSCLC with EGFR exon 20 insertion mutations is promising. However, therapies were assessed in single-arm CTs with low-quality evidence. Comparative studies with more extensive patient follow-up, larger sample size and better design are needed to reliably quantify the effect of these drugs.
Insights
New therapies like mobocertinib, amivantamab, and poziotinib show promise for non-small cell lung cancer (NSCLC) with EGFR exon 20 mutations. However, further high-quality comparative studies are needed to confirm their effectiveness.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations presents a significant therapeutic challenge due to poor prognosis and limited treatment options.
- Identifying effective therapies for this specific patient population is crucial for improving outcomes.
Approach:
- A systematic review of clinical trials was conducted using the PubMed database up to November 19, 2022.
- Trials focused on advanced or metastatic NSCLC with EGFR exon 20 insertions, previously treated with platinum-based chemotherapy, and a minimum sample size of 10 patients were selected.
- Efficacy and safety data were analyzed for identified treatments, with a focus on mobocertinib, amivantamab, and poziotinib.
Key Points:
- Twelve clinical trials evaluated therapies including poziotinib, osimertinib, mobocertinib, amivantamab, and others.
- Mobocertinib, amivantamab, and poziotinib demonstrated promising efficacy in treating NSCLC with EGFR exon 20 insertion mutations.
- Gastrointestinal and dermatological adverse events were commonly observed with these promising regimens.
Conclusions:
- While mobocertinib, amivantamab, and poziotinib show potential, the current evidence is based on single-arm clinical trials with low-quality data.
- High-quality, randomized comparative studies with larger sample sizes and extended patient follow-up are essential to reliably assess the true efficacy and safety of these targeted therapies.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle
00:59Gene Therapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...